



Nutritional advice to breast cancer survivors

ESMO Symposium on Cancer and Nutrition Zurich, 2009

Patrizia Pasanisi, MD, MSc Department of Preventive and Predictive Medicine Epidemiology Unit

Hormonal, metabolic and dietary correlates of breast cancer (BC) risk and recurrences Insulin Metabolic syndrome High fat intake **Growth factors** BC risk & BC recurrences Serum androgens & Body weight estrogens **Sedentary** Life-style

Overweight & Obesity


Overweight and obesity increase the risk of BC after menopause (WCRF,2007).

No association or slitghtly reduced BC risk before menopause. Overweight at menarche is associated with a lower risk of BC in adulthood (differentiation of breast epithelial cells?)

Preventing weight gain in adulthood would decrease the overall burden of BC


Obese BC patients have a poorer prognosis (Dawood S et al., 2008; Rock CL. Et al., 2002; Berclaz G. et al., 2004)

Body weight and prognosis



Physical activity

A sedentary lifestyle is associated with an increased risk of BC both before and after menopause (Vainio H & Bianchini F.,




Sex hormones

Endogenous Hormones and subsequent Breast Cancer


- Before menopause high androgens low progesterone
- After menopausehigh androgenshigh estrogens

Postmenopausal Serum Sex Steroids and BC Risk The EPIC Study; (677 cases / 1309 controls)



0.5

Premenopausal Serum Sex Steroids and Breast Cancer Risk The EPIC Study; (416 cases, 815 controls)



JNCI 2005


ORDET: Premenopausal Breast Cancer Risk by Levels of Sex Steroid Hormones

Serum Concentration (Tertiles)

	Low#	Middle	High	P trend
Total Testosterone	1	0.98	2.63	0.080
		(0.35-2.77)	(0.73-9.50)	
Free Testosterone	1	2.01	3.26	0.055
Free restosterone		(0.63-6.40)	(0.94-5.32)	
Progesterone	1	0.56	0.15	0.006
		(0.19-1.64)	(0.04-0.62)	

#Reference category; adjusted for age, BMI and length of the cycle in which the blood sample was taken, the time interval between the sampling day and the subsequent menses, and the serum levels of LH and FSH (Micheli et al Int J Cancer 2004)

Disease free survival by testosterone level among 194 post-menopausal BC patients who did not receive adjuvant treatments



NOTE. Cancer-event-free survival was estimated by the Kaplan-Meier method; events considered were: local relapse, regional relapse, distant metastases, ipsilateral breast cancer, contralateral breast cancer, and second primary cancer at non breast site. In parentheses the number of women at risk. (Micheli et al JCO, June 2007)

DIANA-2: Hazard ratio of recurrence according to baseline hormonal values

HR (upper vs lower third) Pvalue


	*	**	
◆ Testosterone	7.82		0.00
◆ Estradiol	1.96	0.99	0.98
♦ SHBG	0.53	0.73	0.49
◆ Insulin	1.59	1.91	0.18
♦ IGF-I	1.34	1.10	0.83
Pdgf	1.93	2.19	0.09
 Metabolic syndrome 	2.69	3.01	0.02

(Berrino F. et al., Int J Cancer 2005; Pasanisi P. et al Int J Cancer 2006)

^{*} Adjusted for T, N, ER, PR ** adjusted also for testosterone

Growth factors


RR of breast cancer recurrence by serum levels of IGF-I e PDGF (above or under the median)




Cohort studies on serum IGF-I levels and BC in premenopausal women

Study	Author	Year	n°Ca/Co	RR	(IC 95%)
Nurses	Hankinson	1998	76/105	2.3	(1.1-5.2)
extension S	Shernhammer	2005	218/281	1.6	(2.0-2.6)
	<50 ys		60/ 78	4.6	(1.8-12)
extension S	Shernhammer .	2005	155/193	3.8	(1.7-8.3)
NY WH	Toniolo	2000	172/486	1.6	(0.9-2.8)
	<50 ys		96/280	2.3	(1.1-4.9)
extensi	ion Rinaldi	2005	138/259	1.9	(1.0-3.7)
ORDET	Muti	2002	69/265	3.1	(1.1-8.6)
Kaiser P	Krajcik	2002	66/66	3.5	(0.3-1.4)
Umeå-Malm	ö Kaaks	2002	116/330	0.6	(03-1.4)
HPR	Decensi	2003	45/220	1.9	(0.9-4.3)
Guernsey	Allen	2005	70/209	1.2	(0.6-2.5)
Washington	C. Rollison	2006	175/175	1.4	(08-2.4)
EPIC	Rinaldi	2006	250/491	1.0	(0.6-1.8)
	escluding Ba	C diagnose	es within 2 years	1.9	(1.0-3.4)


<u>Insulin</u>





WHI-OS JNCI 2009: 835 Post-menopausal BC women

HR by serum level of insulin



Goodwin PJ et al. J Clin Oncol 2002;20:42-51

Dietary fats


WINS, Women Initiative on Nutrition Study Chlebowsky 2005 (ASCO), 2006 (JNCI)

	N of randomized patients	N. of recurrences	RR	р
◆ Low fa	t 975	96	0.76	0.034
Contro	1462	181	0.70	0.034
	ER positive	0.85	0.277	
	ER negative	0.58	0.018	
	◆ER - & PR -	0.44	0.004	

WHEL, Women Healthy Eating & Living Pierce 2007 (JAMA)

N.B	C patients	N. of recurrences	RR	Р
◆ Intervention*	1537	256		
◆ Controls	1551	262	0.96	0.63
*	ER+ & PR+ ER - & PR -		0.92 1.13	
· · · · · · · · · · · · · · · · · · ·	P of interac		1.10	0.88
* Diet aimed to lower fa increase vegetable and				

WHEL: energy from fats %




Weight change:



-0.1 Kg

Mechanisms linking nutrition and BC risk



DIANA (DIet and ANdrogens)-5

Randomized controlled trial to test the efficacy of dietary change and physical activity to prevent the development of recurrences in BC patients estimated to be at high risk on the basis of their hormonal or metabolic pattern



Recruitment of about 4000 BC patients
Selection of 2000 women at high risk

Randomization by age, estrogens receptors, tumour stage

Intervention

WCRF recommendations

DIANA-5


- To Riduce calories, through the preferred consumptions of highly satiating foods, such as unrefined cereals, legumes and vegetables.
- To reduce high glycaemic index food, such as refined flours, potatoes, white rice, corn flakes, and high insulinemic foods, such as sugar and milk, preferring instead whole grain rice, barley, millet, oat, spelt, quinoa and buckwheat, legumes (any type including traditional soy products), vegetables (any type, except potatoes)
- To reduce sources of saturated fat (red and processed meat, milk and dairy products) preferring instead unrefined vegetable fats, such as olive oil, nuts and oleaginous seeds.
- To reduce proteins, mainly animal (except fish)
- To achieve and maintain regular participation in a moderate intensity physical activity (approximately 3 to 5 METs) program of 210 minutes/week (30 min on average per day) over at least 3 days /week



FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI



Thank you for your kindly attention!



Patrizia Pasanisi, MD, MSc
Department of Preventive and Predictive Medicine
Epidemiology Unit